Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr37.00 SEK
Change Today 0.00 / 0.00%
Volume 22.3K
HMED On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
As of 11:29 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

hansa medical research ab (HMED) Snapshot

Open
kr36.20
Previous Close
kr37.00
Day High
kr37.20
Day Low
kr36.20
52 Week High
02/10/15 - kr70.76
52 Week Low
05/30/14 - kr12.77
Market Cap
1.2B
Average Volume 10 Days
33.2K
EPS TTM
kr-1.06
Shares Outstanding
32.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HANSA MEDICAL RESEARCH AB (HMED)

Related News

No related news articles were found.

hansa medical research ab (HMED) Related Businessweek News

No Related Businessweek News Found

hansa medical research ab (HMED) Details

Hansa Medical AB, a clinical stage drug development company, focuses on developing novel immunomodulatory enzymes for the treatment of rare and acute conditions characterized by pathogenic antibodies. The company’s lead drug candidate is IdeS, an antibody degrading enzyme, which is in Phase II study for use in transplantation and rare autoimmune diseases. It also develops HBP-assay, a diagnostic method for predicting severe sepsis at emergency wards; and is involved in the research project of EndoS, an antibody-modulating bacterial enzyme to modify the sugar structure of antibodies, as well as to treat the autoimmune diseases and other inflammatory conditions, such as autoimmune hemolysis, systemic lupus, and glomerulonephritis. Hansa Medical AB was founded in 2001 and is headquartered in Lund, Sweden.

14 Employees
Last Reported Date: 04/16/15
Founded in 2001

hansa medical research ab (HMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hansa medical research ab (HMED) Key Developments

Hansa Medical AB Appoints Göran Arvidson as President and CEO, Effective from April 30, 2015

Hansa Medical AB announced that Göran Arvidson joined the company as CFO on January 27, 2015. On March 2, he was appointed acting CEO of the company. Göran's previous positions include Executive Vice President and CFO of Swedish Orphan Biovitrum AB (publ), Co-founder and CFO of Biovitrum, as well as several senior positions in corporate development and finance with Pharmacia AB and Procordia AB. This appointment is with effect from April 30, 2015.

Hansa Medical AB Announces Unaudited Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

Hansa Medical AB announced unaudited consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales of SEK 3,847,000 against SEK 1,612,000 a year ago. The increase is attributable to increased revenues from the partnership with Axis-Shield and comprised of licensing and royalty income from Axis-Shield. Operating result was negatively impacted by increased activity level together with the continued expansion of the organization, but also cost for the planned listing on Nasdaq OMX and transition to IFRS. Total operating income was SEK 4,505,000 against SEK 1,612,000 a year ago. Operating loss was SEK 10,689,000 against SEK 5,896,000 a year ago. Net loss attributable to parent company shareholders was SEK 10,725,000 against SEK 5,998,000 a year ago. Loss per diluted share was SEK 0.41 against SEK 0.26 a year ago. Cash flow from the operating activities was SEK 7,862,000 against SEK 2,779,000 a year ago. Acquisition of tangible fixed assets was SEK 199,000 against SEK 60,000 a year ago. Loss before tax was SEK 10,725,000 against SEK 5,998,000 a year ago. On parent basis for the quarter, the company reported net sales of SEK 3,847,000 against SEK 1,612,000 a year ago. Total operating income was SEK 4,505,000 against SEK 1,612,000 a year ago. Operating loss was SEK 10,684,000 against SEK 5,898,000 a year ago. Net loss was SEK 283,000 against SEK 5,998,000 a year ago. Loss per diluted share was SEK 0.41 against SEK 0.26 a year ago. Cash flow from the operating activities was SEK 7,862,000 against SEK 2,779,000 a year ago. Acquisition of tangible fixed assets was SEK 199,000 against SEK 60,000 a year ago. Loss before tax was SEK 10,283,000 against SEK 5,998,000 a year ago.

Hansa Medical Announces Management Changes

Hansa Medical’s CFO Göran Arvidson has been appointed acting CEO during Fredrik Lindgren’s leave of absence. Fredrik Lindgren has, due to medical reasons, been granted leave of absence by the Board of Directors. After medical consultation, the Chief Executive Officer of the company, Fredrik Lindgren, has requested a leave of absence in order to focus on his health. Göran Arvidson is CFO of Hansa Medical since January 27, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HMED:SS kr37.00 SEK 0.00

HMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HMED.
View Industry Companies
 

Industry Analysis

HMED

Industry Average

Valuation HMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 141.9x
Price/Book 24.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 174.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANSA MEDICAL RESEARCH AB, please visit www.hansamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.